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Abstract
Candida albicans, the major fungal pathogen of humans, causes life-threatening infections in immunocompromised
individuals. Due to limited available therapy options, this can frequently lead to therapy failure and emergence of drug
resistance. To improve current treatment strategies, we have combined comprehensive chemical-genomic screening in
Saccharomyces cerevisiae and validation in C. albicans with the goal of identifying compounds that can couple with the
fungistatic drug fluconazole to make it fungicidal. Among the genes identified in the yeast screen, we found that only AGE3,
which codes for an ADP-ribosylation factor GTPase activating effector protein, abrogates fluconazole tolerance in C.
albicans. The age3 mutant was more sensitive to other sterols and cell wall inhibitors, including caspofungin. The deletion of
AGE3 in drug resistant clinical isolates and in constitutively active calcineurin signaling mutants restored fluconazole
sensitivity. We confirmed chemically the AGE3-dependent drug sensitivity by showing a potent fungicidal synergy between
fluconazole and brefeldin A (an inhibitor of the guanine nucleotide exchange factor for ADP ribosylation factors) in wild
type C. albicans as well as in drug resistant clinical isolates. Addition of calcineurin inhibitors to the fluconazole/brefeldin A
combination only initially improved pathogen killing. Brefeldin A synergized with different drugs in non-albicans Candida
species as well as Aspergillus fumigatus. Microarray studies showed that core transcriptional responses to two different drug
classes are not significantly altered in age3 mutants. The therapeutic potential of inhibiting ARF activities was demonstrated
by in vivo studies that showed age3 mutants are avirulent in wild type mice, attenuated in virulence in
immunocompromised mice and that fluconazole treatment was significantly more efficacious when ARF signaling was
genetically compromised. This work describes a new, widely conserved, broad-spectrum mechanism involved in fungal drug
resistance and virulence and offers a potential route for single or improved combination therapies.
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Introduction
Invasive fungal infections pose a serious health risk to
hospitalized patients worldwide. Particularly affected are immu-
nocompromised individuals with cancer or AIDS, people
undergoing organ and hematopoietic stem cell transplantation
(HSCT), and those receiving immunosuppressive therapy or
implantable prosthetic devices [1,2]. The growing population of
these at-risk groups is reflected in an increase in invasive fungal
infection over the last three decades [3]. Annual treatment costs
for fungal therapies reach $2.6 billion in the US alone [4]. Despite
available therapy options mortality rates approaching 30–50%
(Candida species) and 30–80% (Aspergillus species) remain high [5,6].
Candida and Aspergillus species together account for ,70% of all
invasive fungal infections, with Candida albicans and Aspergillus
fumigatus predominating [7,8,9]. Currently, three classes of
antifungal drugs are suitable for treatment of systemic infections
caused by these fungi: polyenes (most notably amphotericin B) and
azoles (e.g. fluconazole, FCZ) have been applied for decades, while
the echinocandins (e.g. caspofungin, CF) represent a new class of
antifungal that has entered treatment regimes over the past 10
years [10,11]. While these therapy options can be effective, they
also exhibit several shortcomings. First, current antifungals target a
very limited number of biological processes. The majority of
available drugs target ergosterol (polyenes) or inhibit lanosterol
14a-demethylase (azoles), resulting in the accumulation of toxic
sterol intermediates that disrupt membrane integrity and lead to
membrane stress. Because ergosterol, the major sterol in fungal
cell membranes, is analogous to the mammalian lipid cholesterol,
this strategy, particularly when amphotericin B is applied, can be
problematic due to host toxicity [10]. Another complication of
current antifungal strategies is that available drugs each possess a
different spectrum of antifungal activities. For instance, azoles are
typically fungistatic against pathogenic yeasts such as Candida
species, but fungicidal against molds (Aspergillus species). CF, on the
other hand, is fungicidal against yeasts and fungistatic against
molds [12]. Finally, and most importantly, the small number of
treatment options available has resulted in widespread drug
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classes of antifungals (polyenes, azoles, echinocandins) isolation of
drug-resistant clinical strains has been reported [11,12,13]; azole-
resistant Candida, in particular, is now common among isolates
from HIV-positive patients [14]. Developing new antifungal
strategies, therefore, remains a pressing need.
One approach to satisfy this need is through combination
antifungal therapy, where two (or more) agents combined are
significantly more efficacious compared to either agent alone. This
approach has recently been validated in a randomized, placebo-
controlled trial, where approved antifungals were combined with
immune regulatory agents [15]. Results from this study suggested
that combining ergosterol inhibitors with a recombinant human
monoclonal antibody against heat-shock 90 protein (HSP90)
showed increased therapeutic benefits compared to monotherapy
against Candida infection. Although the precise mechanisms
involved remain elusive [16], extensive experiments have further
established the benefits of such combinatorial approaches. For
instance, a potent synergy resulted when inhibitors of HSP90
(geldanamycin, radicicol) or inhibitors of HSP90’s key client
protein, calcineurin (cyclosporin A (CsA), FK506) were combined
either with azoles or echinocandins against C. albicans
[10,16,17,18,19,20,21]. Similarly, pharmacological compromise
of HSP90/calcineurin-signaling enhanced the efficaciousness of
echinocandin treatment against A. fumigatus in vitro as well as in
insect and mouse infection models [16,17]. Although these
examples clearly demonstrate the potential for combination
antifungal therapy, human host toxicity associated with inhibition
of HSP90 or suppression of the human immune system by CsA/
FK506 currently precludes the use of such inhibitors in the clinic
[16,22]. While a non-immunosuppressive FK506 analogue (L-685,
818) has been identified, proprietary restrictions have currently
prevented further testing [22]. Therefore, identification of new
antifungal targets for optimal fungal killing remains a priority.
One of the challenges of finding new antifungal targets in C.
albicans is the lack of sophisticated screening technologies often
employed with, for example, Saccharomyces cerevisiae. Various large-
scale chemical-genomic drug screening methods are now well
established in S. cerevisiae, and have been effective for elucidating
drug targets or revealing insights into the modes of action of
bioactive compounds [23,24,25,26,27]. Similar approaches have
only recently been applied directly to fungal pathogens [28]. Using
S. cerevisiae as a model, we previously performed chemical-genomics
to systematically analyze the genetic requirements to survive FCZ
treatment [29]. In that work, we identified 22 genes that become
essential for S. cerevisiae survival in the presence of FCZ.
Here, we expanded that work with the aim of identifying
synergistic drug interactions that render FCZ fungicidal in C.
albicans. To this end, we validated the S. cerevisiae FCZ-cidal gene
set [29] in C. albicans. From 22 predicted genes, we found that only
one gene, AGE3, mediated FCZ tolerance in the pathogen. We
further show that both genetic and pharmacological compromise
of ARF (ADP ribosylation factor) activities, a process that depends
on Age3p, creates sensitivity to all three classes of antifungals used
in clinics (polyenes, azoles, echinocandins), overrides clinical drug
resistance and the calcineurin pathway, synergizes with fungistatic
drugs against the two major pathogenic fungal species (C. albicans
and A. fumigatus) and modifies fungal virulence in two established
mouse models of candidiasis. Given that drug treatment in mice
was significantly more efficacious when ARF activity was
genetically compromised, this demonstrates that targeting ARF
signaling has potential for antifungal therapies.
Results
Age3p mediates azole tolerance and sensitivity to cell
wall inhibitors in C. albicans
To identify genes that become essential for survival in the
presence of FCZ, we previously screened the non-essential S.
cerevisiae knock-out collection (about 4900 strains) and identified 22
mutants that showed a robust FCZ-cidal phenotype [29]. BLAST
searches identified C. albicans homologs for 21 of those S. cerevisiae
genes. YDR532c appears to be the only gene that lacks a clear C.
albicans homolog (Table S1). Recreating knockout or transposon
insertion mutations of the 21 candidate genes in C. albicans,w e
found that four mutants (bem2, sac6, srb8 and ssn3) showed FCZ
sensitivity comparable to WT (Table S2, Figure S1). Twelve C.
albicans mutants (57%) showed increased FCZ sensitivity, but all of
these mutants could still resume growth when incubated for
extended time in the presence of FCZ. Four genes (GCN5, NGG1,
ERG11 and NUP84) were linked to a slightly resistant FCZ
phenotype. Only one mutant, age3 (ORF19.3683), showed the FCZ
sensitive phenotype predicted from the yeast screen. We therefore
focused further investigation on AGE3.
We validated the FCZ sensitivity of age3 cells by three different
assays. When tested in a minimal inhibitory concentration (MIC)
assay, the age3 mutant initially showed similar drug sensitivity as
WT and revertant strains at 24 hours. Since FCZ on its own is
fungistatic, however, WT cells demonstrated robust growth above
the initial MIC point after prolonged incubation (72 hours), a
feature referred to as tolerance [19]. In contrast, age3 cells did not
resume growth above the 24 hours MIC point, indicating that age3
mutants lost tolerance to FCZ (Figure 1A, Table S2). These results
were confirmed visually by growth on solid rich media in the
presence of FCZ (Figure 1B). We further characterized the FCZ
sensitivity of age3 cells by time-kill curves. Under FCZ treatment,
the number of viable age3 cells slightly decreased over time, while
growth of WT cells in the presence of FCZ continued (Figure 1C).
Author Summary
Candida albicans is a fungus that normally resides as part
of the microflora in the human gut. Candida species can
cause superficial infections like thrush in the healthy
human population and life-threatening invasive infections
in immunocompromised patients. Fungal infections are
often treated with azole drugs, but due to the fungistatic
nature of these agents, C. albicans can develop drug
resistance, leading to therapy failure. To improve the
action of azoles and convert them into fungicidal drugs,
we first systematically analyzed the genetic requirements
for tolerance to one such azole drug, fluconazole. We
show, both genetically and pharmacologically, that com-
ponents of the ARF cycling machinery are critical in
mediating both azole and echinocandin tolerance in C.
albicans as well as several other pathogenic Candida
species and in the pathogenic mold Aspergillus fumigatus.
We highlight the importance of ARF cycling in drug
resistance by showing that genetic compromise of ARF
functions overrides common drug resistance mechanisms
in clinical samples and other key regulators of azole/
echinocandin tolerance. We validated the therapeutic
potential of ARF cycling in two mouse models and provide
evidence that drug treatment is more efficacious when
ARF activities are genetically compromised. Our study
demonstrates a new mechanism involved in two impor-
tant aspects of the biology of human fungal pathogens
and provides a potential route for improved antifungal
therapies.
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to gauge the specificity of the mutation. We included various
compounds, including second-generation azoles (voriconazole),
non-azole ergosterol inhibitors (terbinafine) and other membrane-
targeting drugs (amphotericin B). We found that age3 cells showed
a generalized increased sensitivity to these compounds
(Figure 1D). Among all cell-membrane drugs tested, the azoles
caused by far the most significant enhancement in sensitivity in
the age3 mutant.
In order to determine the effect of deleting AGE3 on the
integrity of the cell wall, we tested the age3 mutant for sensitivity to
a variety of cell wall perturbing agents and other agents whose
effect have been linked to altered cell wall and glycosylation. The
age3 mutant was slightly more sensitive to the b-1,3 glucan
synthase inhibitor CF. Similarly, age3 cells were slightly more
sensitive to calcofluor white, a phenotype that is usually associated
with altered chitin structures along the cell wall [30]. More
remarkably, age3 cells were extremely sensitive to hygromycin B, a
phenotype usually seen in glycosylation mutants [31,32]
(Figure 1D, 1E). No change in sensitivity was observed in the
presence of other agents such as caffeine, cycloheximide,
menadione, nocodazole, rapamycin, 5-FC and wortmannin (data
not shown). Together, these data suggest that while AGE3 plays a
major role during membrane stress in C. albicans, its influence on
the integrity of the cell wall remains somewhat less clear (see
discussion).
Figure 1. Age3p plays a major role in azole tolerance in C. albicans. (A) Minimal Inhibitory Concentration (MIC) assay in rich YPD media
showing that age3 cells are initially almost equally sensitive to FCZ compared to WT and revertant strains (24 hours reading, top), but fail to grow
above this MIC threshold after prolonged incubation (72 hours reading, middle). MIC assays with two-fold serially diluted drug concentrations were
done in duplicate and optical densities were normalized to drug-free control wells (see color bar). After 72 hours of incubation, 2 ml of each well of
the MIC assay was spotted on fresh YPD media to assess the extent to which cells recover from the drug treatments (bottom). YPD recovery plates
were incubated for 24 hours at 30uC. (B) FCZ sensitivity assayed on solid YPD media. No age3 colonies grew on YPD plates containing 24 hours-supra-
MIC concentrations of FCZ. Overnight cultures were adjusted to OD600 of 0.1, and then serially diluted four-fold, before 2 ml were spotted on plates.
Plates were incubated for 48 hours at 30uC. (C) Time-kill curves in YPD media confirming that knocking out AGE3 abrogates tolerance to FCZ. The
number of viable age3 cells decreases slightly over time, while growth of WT cells in the presence of FCZ still occurs. FCZ was used at 10 mg/ml.
Shown is the average of two independent experiments plus SD values. Note that age3 cells grow as efficiently as WT cells in the absence of drugs. (D)
MIC assays in YPD media shows that age3 mutants are extremely sensitive to numerous azoles after 48 hours and mildly more sensitive to non-azole
ergosterol inhibitors (terbinafine, amphotericin B) as well as cell wall inhibitors when compared to WT cells. Fold reduction represents the ratio of the
MIC value for WT over the MIC value of the age3 mutant. (E) age3 cells show differential sensitivity to different cell wall inhibitors on YPD media
plates. The assay was done as described in (B).
doi:10.1371/journal.ppat.1000753.g001
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calcineurin pathway
Among the most commonly encountered resistance mechanisms
in drug treated clinical C. albicans isolates are over-expression of
drug pumps or alterations in sterol biosynthesis [13,33,34]. To test
whether such common mechanisms of drug resistance are still
effective in the absence of AGE3, we deleted AGE3 in two FCZ-
resistant clinical strains. The strain F5 carries a mutation in the
transcription factor MRR1, which leads to constitutive over-
expression of drug pumps. The strain S2 carries a mutation in the
transcription factor UPC2, which causes up-regulation of ergos-
terol biosynthesis genes [35,36]. Figure 2A shows that deleting
AGE3 in strains F5 and S2 restored FCZ sensitivity even below
WT levels, suggesting that loss of AGE3 abrogates FCZ-resistance
in these clinical isolates.
Because age3 mutants lost tolerance to FCZ and because the
calcineurin pathway is known to mediate FCZ-tolerance in WT as
well as drug resistant clinical isolates [10,19], we tested whether
constitutive calcineurin signaling could reverse the AGE3-depen-
dent FCZ sensitivity. The calcineurin pathway can be activated by
addition of extracellular CaCl2 [19]. C. albicans WT became
resistant to FCZ after only 24 hours of growth in the presence of
extracellular CaCl2, while this rescue was not observed in the
absence of AGE3 (Figure 2B). To further verify this observation, we
deleted AGE3 in a constitutively active calcineurin signaling
mutant (DSY2146) that is resistant to FCZ even in the absence of
extracellular CaCl2 [19]. Deleting AGE3 in this constitutively
active calcineurin mutant restored FCZ sensitivity both in the
absence and in the presence of extracellular CaCl2 (Figure 2B).
These results suggest that constitutive calcineurin signaling does
not rescue the age3-dependent FCZ sensitivity. The results also
support an argument that AGE3 and calcineurin-dependent
processes could be linked (see discussion).
Pharmacological compromise of ARF cycling converts
FCZ into a fungicidal drug in C. albicans
Given AGE3’s role in sensitivity to various drugs and its
implication in clinically relevant processes such as drug resistance,
targeting either AGE3 or its biological process seemed a plausible
avenue for combination therapies to render FCZ fungicidal. The
S. cerevisiae homolog of C. albicans AGE3 is GCS1, which encodes an
ARF GAP (ADP-Ribosylation Factor GTPase Activating Protein)
[37]. ARFs are small G-proteins of the Ras GTPase superfamily
that cycle between an active GTP-bound and an inactive GDP-
bound state. ARF guanine nucleotide cycling, and hence function,
is regulated by GAPs and GEFs (guanine nucleotide exchange
factors) [38]. ARFs are involved in a variety of processes including
vesicle trafficking (Golgi-to-ER retrograde vesicle trafficking, trans
Golgi network-endosomal transport, transport from the Golgi to
the membrane) and actin cytoskeleton organization [39,40,41,42].
Brefeldin A (BFA), a metabolite from the fungus Penicillium
decumbens, is a noncompetitive inhibitor of ARF activity. Protein
crystal structures showed that BFA binds to a ternary complex of
ARF-GDP-GEF, thus stabilizing this otherwise transient protein-
protein interaction [43,44,45,46,47,48]. Given that ARF cycling is
a well-established target of BFA, we reasoned that BFA might be
Figure 2. Deleting AGE3 overrides clinical drug resistance and the calcineurin pathway. (A) When AGE3 is knocked out in drug resistant
clinical isolates F5 and S2, FCZ sensitivity is restored even below WT levels on solid YPD media. The assay was performed and analyzed as described in
Figure 1B except plates were photographed after 24 hours. GOF=gain of function. (B) Calcineurin signaling stimulated either by extracellular CaCl2 or
by a constitutively active mutation in strain DSY2146 leads to FCZ resistance. age3 mutants do not respond to extracellular CaCl2, while knocking out
AGE3 in strain DSY2146 restored FCZ sensitivity. Disc diffusion assays were done by plating 2610
5 cells on YPD plates followed by applying discs
containing 50 mg of FCZ to the surface of agar. Plates were incubated for 24 hours at 30uC.
doi:10.1371/journal.ppat.1000753.g002
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chemically mimicking the age3-dependent FCZ sensitivity. As
illustrated by time-kill curves in Figure 3A, combining FCZ with
BFA resulted in a potent fungicidal synergy in WT C. albicans,
while either drug alone had only minor effects on cell growth. To
compare the BFA/FCZ synergy to a well-established fungicidal
synergy, we repeated the time-kill curves with CsA in combination
with FCZ. CsA/FCZ co-treatment resulted in a similarly strong
synthetic phenotype after 24 hours. This observation corroborates
previous findings that calcineurin inhibition plus FCZ results in a
potent fungicidal combination as assayed at 24 hours of drug
treatment [19]. A triple drug combination of FCZ/BFA/CsA was
significantly more efficacious than either FCZ/CsA or FCZ/BFA
alone at 24 hours. However, when monitored for more than
24 hours, conditions that have not previously been reported [19],
cells treated with FCZ/CsA could recover and resume growth,
while cells treated with FCZ/BFA or FCZ/BFA/CsA could not
resume growth above the detection limit (<10 cells/ml). At
72 hours, drug combinations of either FCZ/BFA or FCZ/BFA/
CsA appeared equally efficacious with no evidence of growth,
while cells treated with FCZ/CsA continued to proliferate. Similar
results were obtained when another calcineurin inhibitor, FK506,
was combined with FCZ. These results suggest that while the
combination of calcineurin inhibitors and an azole is initially
efficient in pathogen killing, over prolonged drug treatment,
combining ARF inhibitors with azoles is more efficacious.
A dose-matrix titration assay measuring growth of treated cells
confirmed the synergy between FCZ/BFA (Figure 3B, Table S3).
Figure 3. Pharmacological inhibition of ARF cycling results in a potent, fungicidal synergy in combination with FCZ in C. albicans. (A)
Time-kill curves demonstrating that, while combining FCZ and BFA was initially equally efficacious in pathogen killing compared to combining FCZ
and calcineurin inhibitors (FK506 or CsA), extended drug exposure only remained efficacious in pairwise BFA/FCZ combinations. Triple drug
combinations of BFA/FCZ/calcineurin inhibitors were only initially (24 hours) more efficacious, but at 72 hours appeared equally efficacious
compared to BFA/FCZ. The assay was done in YPD media. Drugs were used at 10 mg/ml for FCZ, 15 mg/ml for BFA, 1 mg/ml for CsA and 1 mg/ml for
FK506. (B) Dose-matrix titration assay confirming the FCZ/BFA synergy in WT and drug resistant clinical isolates 5674, S2 and F5 in rich YPD media
(top). Dose-matrix titration plates were incubated for 72 hours after which aliquots of each well were spotted on fresh YPD recovery plates (bottom).
No-growth of recovery plates confirmed fungal cell death of the drug synergy. Recovery plates were incubated for 24 hours. Dose-matrix titration
assays were analyzed as described for MIC assays in Figure 1A.
doi:10.1371/journal.ppat.1000753.g003
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albicans drug resistant clinical isolates and found that, although
considerably higher concentrations of FCZ were needed, there was
synergy in isolates F5 and S2 as well as in isolate 5674, which
carries a gain-of-function mutation in TAC1, a transcriptional
activator of CDR drug efflux pump genes [49]. Thus, genetic
compromise of ARF cycling by deleting AGE3 abrogated FCZ
tolerance, while pharmacological compromise of ARF cycling by
adding BFA converted the fungistatic drug FCZ into a fungicidal
agent in WT and FCZ-resistant C. albicans clinical isolates.
Together, this suggests that the process of ARF cycling becomes
essential during cell membrane stress in this pathogen.
Combining ARF inhibition with other drugs across fungal
species
Importantly, genetic or pharmacological compromise of ARF
cycling did not appear to significantly affect the cells’ initial
response to FCZ (Figure 1A, 3B, Table S2). Instead, ARF cycling
inhibition seems to act on tolerance. To test whether the effect of
BFA on tolerance is observed in combination with other azole
drugs, we tested miconazole (MICO) and ketoconazole (KETO) in
combination with BFA, because MICO and KETO alone did
show a tolerance effect (Figure 4A). When tested in a dose-matrix
titration format, BFA synergized with MICO and KETO against
WT C. albicans, independently of which media were used
(Figure 4A, Figure S2).
Although CF is generally considered fungicidal in C. albicans,w e
tested whether BFA would synergize with CF. Recent reports
showed that C. albicans can start to grow at supra MIC
concentrations of CF, an outcome referred to as the paradoxical
or trailing growth effect [50,51]. BFA did synergize with CF against
WT C. albicans in a dose matrix titration assay at supra MIC
concentrations of CF (Figure 4B). Together, these results indicate
that genetic and pharmacological compromise of ARF cycling
influences not only cell membrane stress, but also cell wall stress.
To examine whether BFA’s inhibition of azole tolerance is
conserved across other pathogenic Candida species, we tested BFA/
drug interactions in C. tropicalis, C. parapsilosis, C. glabrata and C.
krusei. Together, these species account for ,30–40% of all Candida
isolates causing invasive infections; furthermore, C. glabrata and C.
krusei are notoriously difficult to treat with FCZ [7,8,12]. C.
tropicalis, C. parapsilosis and C. glabrata showed tolerance in the
presence of FCZ, MICO and KETO (Figure 5A); these azoles
synergized with BFA in dose-matrix titration assays with these
fungi. FCZ also synergized with BFA in the non-pathogenic yeast
S. cerevisiae (data not shown). On the other hand, C. krusei did not
show an obvious tolerance effect (i.e. .2 fold variations between
24 hours and 72 hours MIC readings), which could explain why
BFA did not synergize with azoles in this pathogen (Figure 5B).
To further investigate ARF cycling inhibition as a mechanism
of abrogating drug tolerance in non-Candida human fungal
pathogens, we asked whether BFA would synergize with FCZ or
CF against A. fumigatus. Consistent with the idea that ARF
cycling inhibition acts primarily on tolerance, a disc diffusion
assay in A. fumigatus demonstrated that BFA synergized with CF,
ad r u gt h a ti sg e n e r a l l yf u n g i s t a t i ci nA. fumigatus (Figure 6). CF
treatment created an inhibition zone against A. fumigatus where
cells could still grow within that zone due to the fungistatic
nature of CF. In contrast, when BFA was combined with CF,
not only was the size of that inhibition zone increased, but
growth within that zone was also remarkably reduced. A MIC
assay in defined synthetic media independently confirmed that
CF synergized with BFA against A. fumigatus (Table S3). On the
other hand, we found that BFA did not synergize with FCZ, a
drug that is considered fungicidal in A. fumigatus (data not
shown) [12]. In general, pharmacological compromise of ARF
cycling in A. fumigatus w a sn o ta se f f i c a c i o u sa si nCandida species,
possibly because BFA on its own had a more pronounced
impact on growth of A. fumigatus compared to Candida species
(Figure 6, Table S3). Taken together, these results show that
Figure 4. Pharmacological compromise of ARF cycling synergizes with various azoles as well as the cell wall inhibitor CF. (A) MIC
assays in YPD media demonstrated that WT C. albicans shows tolerance to MICO and KETO (top, compare 24 hours to 72 hours MIC readings).
Combining BFA with either MICO or KETO resulted in a similarly potent fungicidal combination compared to BFA/FCZ (bottom). (B) CF showed
trailing growth in rich YPD media (top) and synergized with BFA in a dose-matrix titration assay (bottom) against WT C. albicans. MIC and dose-matrix
titration assays were performed and analyzed as described in Figure 1A and 3B, respectively.
doi:10.1371/journal.ppat.1000753.g004
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PLoS Pathogens | www.plospathogens.org 6 February 2010 | Volume 6 | Issue 2 | e1000753Figure 5. BFA synergizes with different azoles in pathogenic non-albicans Candida species. (A) When treated with FCZ, MICO or KETO, C.
tropicalis, C. parapsilosis and C. glabrata isolates showed prominent growth above the initial MIC reading after extended incubation (24 hours vs.
72 hours). Dose-matrix titration assays confirming that BFA synergized with the three azoles in all three species. (B) No obvious tolerance effect was
observed in C. krusei to any azoles tested and no synergy was observed when BFA was combined with these azoles. MIC and dose-matrix titration
assays were performed and analyzed as described in Figure 1A and 3B.
doi:10.1371/journal.ppat.1000753.g005
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drugs in many pathogenic fungi to generate potentially
fungicidal activity.
Core transcriptional responses to FCZ and CF treatment
are not significantly affected in the absence of AGE3
Analysis of transcriptional regulation has frequently been used
to elucidate which cellular processes are linked to drug sensitivity
or drug resistance in C. albicans [35,52,53]. We therefore
performed microarray studies to test how transcriptional regula-
tion is altered in age3 mutants. We first compared WT to age3 cells
in the absence of drugs and found that 23 genes were differentially
regulated when AGE3 was absent (Table S4). Among those 23
genes were five GPI-anchored cell wall proteins (ECM331, PGA13,
CRH11, SAP9, PGA26) and two genes with phospholipase activity
(FGR22 and PI-PLC). Because none of these genes have been
linked to FCZ tolerance, it is currently unclear how they might
influence the age3-dependent drug phenotypes.
We next analyzed the transcriptional response to FCZ. A typical
transcriptional signature to FCZ is upregulation of ergosterol
genes, presumably to compensate for depletion of these membrane
lipids [54,55]. This core response to FCZ was not changed in the
absence of AGE3. All ergosterol genes that became significantly
upregulated in FCZ-treated WT cells were similarly upregulated
in FCZ-treated age3 cells (Table S5). Besides this core response to
FCZ, clustering analysis of genes that were significantly regulated
(.2 fold expression change and p-value ,0.05) further confirmed
that the overall transcriptional response to FCZ was very similar in
WT and age3 cells (Figure S3A, Table S6).
A similar lack of AGE3-dependent transcriptional consequences
could be observed in microarray experiments when the cell wall
inhibitor CF was used. Clustering analysis revealed that CF-
treated WT cells and CF-treated age3 cells showed an almost
identical transcriptional response, with a significant overlap (p-
value 4.8610
2194) of differentially regulated genes (Figure S3B,
Tables S7, S8). This overlap of 168 genes showed further
statistically significant similarity (p-value 1.8610
27) when com-
pared to core C. albicans CF-responsive genes previously identified
in two independent studies [52,56]. Therefore, the core transcrip-
tional response to CF in C. albicans seems not to depend on AGE3.
In summary, these microarray experiments suggest that deleting
AGE3 does not cause major transcriptional changes in the
presence of two different drug classes and further indicates that
post-transcriptional processes might play a more dominant role in
terms of ARF cycling-dependent drug phenotypes.
The age3 mutant is avirulent in WT mice
To evaluate whether AGE3 is a good drug target in vivo,w ef i r s t
injected age3 mutant cells into WT B6 mice, and found that age3
cells are avirulent in this mouse model. While 100% of mice
infected with WT C. albicans became moribund within 11 days
post-infection, none of the age3 mutant strain infected mice
became moribund during the same time frame (Figure 7A). To
test whether mice infected with age3 cells had cleared the
infection, we sacrificed half of the mutant group on day 11 to
analyze kidney fungal burden (Figure 7B). On average, kidney
fungal load was significantly reduced (p-value ,0.01, Mann
Whitney test) in the age3 group compared to moribund WT-
infected mice. We continued with the other half of age3 mutant-
infected mice until the end of the experiment (day 21), but again
found that none of the age3-infected mice became moribund.
Comparing fungal load from these mice showed that three mice
had cleared the infection, while two mice had a fungal load that
was comparable to WT-infected mice. On average, however,
there were significantly fewer age3 cells recovered from the
host compared to moribund mice infected with WT C. albicans (p-
value ,0.02, Figure 7B).
One key virulence factor in C. albicans pathogenicity is hyphal
formation [57]. Because Arnold Bito and coworkers (Lettner T.,
Zeidler U., Gimona M., Breitenbach M., Bito A., manuscript
submitted, personal communication from A. Bito) have
observed some hyphal formation defects on solid media as well
as defects in invasive growth in age3 mutants, we collected
kidneys for histological examination on day 11 from both WT-
infected and age3-infected mice. No obvious difference was
found between kidney sections recovered from WT or from age3-
infected mice (Figure 7C). In all kidney sections examined, age3
cells could be observed as elongated hyphal structures.
Therefore, it remains unclear why age3-infected mice with a
high fungal burden did not show any clinical signs, but might
indicate that additional virulence factors are affected in age3
mutants.
Genetic inhibition of ARF cycling results in attenuated
virulence in an immunocompromised mouse model of
disseminated candidiasis and FCZ treatment is
significantly more efficacious when ARF activity is
genetically compromised
To help evaluate the therapeutic potential of FCZ treatment of
age3 mutant-infected mice, we required a mouse model where age3
cells retain at least partial virulence. Cells of the C. albicans strains
Figure 6. BFA synergism with the fungistatic cell wall inhibitor CF in A. fumigatus. BFA/CF interaction in an A. fumigatus disk diffusion assay
on half-strength YPD media. CF alone creates an inhibition zone that still allows fungal growth. Combining CF and BFA abrogated growth within that
zone. Discs containing 160 mg CF were applied after 10
5 conidia were plated on plates containing water only, vehicle control (DMSO) or BFA (16 mg/
ml), as indicated. Plates were incubated for 48 hours.
doi:10.1371/journal.ppat.1000753.g006
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immunocompromised C5-deficient A/J mouse model [58]. In this
very sensitive animal system, C. albicans WT and revertant-infected
A/J mice became rapidly moribund after 20 to 24 hours, while
age3 mutant-infected A/J mice survived significantly longer, with
a median survival of two days (p-value ,0.02, Log-rank test)
(Figure 8A). However, comparing fungal burden indicated that
mice infected with C. albicans age3 cells accumulated a significantly
higher fungal load when moribund (p-value ,0.02), with hyphal
formation still observed in the age3 mutant-infected mice
(Figure 8B, data not shown).
To test whether genetic compromise of ARF activity holds
therapeutic potential, we repeated this experiment and injected
WT, age3 and the revertant strains in A/J mice to compare
survival lengths after two days of FCZ therapy. FCZ adminis-
tration extended survival of all three groups (p-value ,0.001), but
was significantly more efficacious in the mutant-infected mice,
extending median survival time more than 10-fold compared to
7.5-fold median survival time extension for both the WT and
revertant groups (p-value ,0.01 for posthoc comparison between
age3 mutant group with and without FCZ, versus p-value .0.05
posthoc comparison between WT with and without FCZ or p-
value .0.05 for posthoc comparison between revertant with and
without FCZ, Dunnett’s Multiple Comparison) (Figure 8C). In
summary, we conclude from these in vivo experiments that genetic
compromise of ARF cycling results in avirulence in WT mice,
significant attenuation in virulence in an immunocompromised
mouse model and further suggests that FCZ treatment in A/J
mice is more efficacious when ARF cycling is genetically
compromised.
Discussion
Identifying new drug targets is an important step in the
challenging task of developing new antifungal therapies, which are
urgently needed due to the emergence of drug resistance to every
class of antifungals currently in clinical use [11,59]. Using a
comprehensive reverse-genetics screen, we identified Age3p and
the process of ARF cycling as potential new drug targets. We
further established a widely conserved, potent fungicidal chemical
synergy between the ARF cycling inhibitor BFA and several
fungistatic drugs, and, through two murine infection models,
validated the potential of ARF cycling as an antifungal target.
To render FCZ fungicidal through combination with other
drugs, we applied a large-scale chemical-genomic approach in S.
cerevisiae and found 22 FCZ-cidal genes (Table S1) [29]. The S.
cerevisiae screen proved to have predictive power in that 12 of the
22 genes (57%) identified in S. cerevisiae were validated in C. albicans
with an increased FCZ sensitivity (Figure S1, Table S2). Among
those genes, only CDR1 and ADA2 have previously been linked to
FCZ sensitivity in C. albicans [52,60]. On the other hand, our
screen linked four genes to FCZ resistance in the pathogen
(NUP84, ERG11, GCN5 and NGG1). One of those genes, ERG11,
has previously been linked to FCZ resistance in C. albicans [61]. Of
note, Sanglard and coworkers have shown that the C. albicans erg11
mutant was sensitive to a variety of drugs, including BFA [61].
Two other C. albicans genes that have been linked to FCZ
resistance in our screen (GCN5 and NGG1) are part of the SAGA, a
conserved transcriptional co-activator [62]. Our data therefore
expand the known events of transcriptional rewiring between S.
cerevisiae and C. albicans in regards of drug resistance [63,64], as
Figure 7. Genetic compromise of ARF cycling in C. albicans results in avirulence in a WT mouse model of disseminated disease. (A) C.
albicans WT-infected mice become gradually moribund up to day 11, while mice infected with age3 mutants did not show any clinical signs until the
end of the experiment on day 21. The dotted blue line indicates that half of the age3 mutant-infected mice were sacrificed to compare fungal load.
Those mice were not moribund. (B) On average, fungal load of WT-infected mice, when moribund, is significantly higher compared to mutant fungal
burden taken at indicated times. (C) Kidney section of WT-infected mice (left) showing fungal hyphal formation, which is also seen in mutant-infected
kidneys (right). Kidneys were collected on day 11 for histological examination. Ten mice were used per experimental group and monitored according
to approved standards.
doi:10.1371/journal.ppat.1000753.g007
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increased drug sensitivity in our screen as well as in two previous
studies [52,60]. The observation that different subunits of the same
transcriptional co-activator complex regulate the opposing phe-
notypes of drug sensitivity or drug resistance illustrates the extreme
adaptability and flexibility of transcriptional regulatory networks
in fungi.
Given that diverse essential processes exhibit significantly
different regulation in S. cerevisiae and C. albicans [65,66,67],
reorganization of transcriptional regulation might in general
account for C. albicans mutants that showed different drug
phenotypes compared to the yeast prediction. Despite these
considerations, budding yeast genetics remains a convenient and
powerful approach to predict phenotypes in pathogenic fungal
species, at least until similar sophisticated screening techniques
become available in the pathogen itself.
An alternative speculation why the success rate of our screen
was not higher is that the gene encoding ERG11, the target of FCZ
in both species, is essential only in S. cerevisiae [29,61]. Thus, there
may be redundant mechanisms for sterol biosynthesis in C. albicans,
a suggestion that is further supported by the observation that
another ergosterol biosynthesis gene, ERG24, is essential in S.
cerevisiae, but not in C. albicans [68].
Chemical compromise of ARF cycling appeared far more
potent than genetic compromise. When age3 mutants were treated
with FCZ, the number of viable cells was reduced in time-kill
curve experiments by less than one log value, whereas combining
FCZ with BFA reduced the number of viable WT cells more than
one log value over the same time (Figure 1C, Figure 3A). Similarly,
chemical compromise appeared more potent than genetic
compromise in terms of synergy with CF. The age3 mutant was
only 2-fold more sensitive to CF than WT. On the other hand,
combining BFA with CF resulted in a 32-fold reduction in
sensitivity to CF in WT cells (Figure 1D and 1E, Figure 4B). These
differences likely reflect that, while chemical interference with
ARF function inhibits potentially all ARF GEFs, genetic
inactivation was restricted to one ARF GAP (AGE3). Thus, it
remains possible that some aspects of ARF signaling continue to
function in the absence of AGE3 under drug conditions, a
suggestion that is supported by work in yeast that demonstrated
that several ARF GAPs provide redundant functions [39,40].
The finding that both genetic and pharmacological blockage of
ARF function result in increased azole sensitivity suggests that,
among the multiple cellular roles described for the yeast
homologue of AGE3, defects in proper ARF cycling and, therefore,
defects in intracellular vesicle trafficking are responsible for drug
phenotypes. One hypothesis to explain how incorrect vesicle
trafficking could result in age3-dependent drug sensitivity is
mislocalization of drug pumps. However, CDR1 and MDR1, two
major drug pumps in C. albicans appear not be involved, as Arnold
Bito and coworkers (Lettner T., Zeidler U., Gimona M.,
Breitenbach M., Bito A., manuscript submitted, personal com-
munication from A. Bito) observed that CDR1 and MDR1 pumps
are correctly localized to the plasma membrane in age3 mutants.
They further established that CDR1 drug pump activity was not
affected in the absence of AGE3.
Another plausible explanation that could account for the azole
sensitivity of age3 mutants is defects in the biosynthesis of ergosterol
or problems in transporting this membrane lipid to the cell
membrane. Our microarray experiments provided evidence that
the target pathway of azoles is not affected transcriptionally in the
presence or the absence of FCZ (Figure S3A, Tables S5 and S6).
We further found that the amount of ergosterol is similar in the
plasma membrane of age3 mutants compared to WT (our
Figure 8. age3 mutants are attenuated in virulence in A/J mice
and FCZ treatment significantly extends survival of age3-
infected A/J mice. (A) age3 mutant-infected mice survive significantly
longer with a median survival of two days versus one day for WT and
revertant-infected mice. Six mice were used per experimental group. (B)
Fungal kidney burden was examined from moribund mice and was
significantly higher in age3 mutant recovered cells compared to WT or
revertant control groups. (C) A short FCZ therapy (4.5 mg/kg
intraperitoneally once immediately after fungal infection, once on day
one and once on day two post fungal infection) is significantly more
efficacious when ARF cycling is genetically compromised as only the
majority (83%) of mutant-infected mice survive until the end of the
experiment (day 21). Six mice were used for WT and revertant groups
and 12 mice for the age3 mutant group.
doi:10.1371/journal.ppat.1000753.g008
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ments showing that deletion of AGE3 restored azole sensitivity in
different clinical isolates, suggest that the azole sensitivity of age3
cells is unlikely to depend on established mechanisms.
Finally, in support of the vesicle transport hypothesis is the
observation that while age3 cells showed slightly increased
sensitivity to different cell wall perturbing agents (CF and
calcofluor white), the most impressive effect besides azoles was
observed when age3 cells were treated with hygromycin B
(Figure 1D). Hygromycin B sensitivity is usually linked to
glycosylation defects [31,32]. Therefore, it remains possible that
some glycosylated proteins, including GPI-anchored proteins that
normally reside in the cell wall, are not properly localized in age3
cells. How precisely defects in vesicle trafficking influence the
observed drug phenotypes and whether drug sensitivity is caused
by a general aspect of the secretory pathway or of a particular cell
membrane or wall protein remains to be determined.
Drug resistance and virulence are two important biological
aspects of pathogenic fungal species. While different fungal drug
resistance mechanisms are now well understood [69,70], various
virulence-related attributes have been described that help Candida
to cause infections [57,59,71]. Whereas genes critically involved
either in drug resistance or virulence are attractive drug targets
[59], an undeniably better option is targeting genes that are
involved in both processes. The broad-range sensitivity to azoles
and an echinocandin together with in vivo data showing that age3
mutants are avirulent in WT and exhibit significantly attenuated
virulence even in an immunocompromised mouse model, indicates
that Age3p and the process of ARF cycling is one such option. We
further explored the therapeutic potential of ARF cycling
inhibition by demonstrating that, in A/J mice, FCZ treatment
was significantly more efficacious when ARF activity was
genetically compromised.
One of our major problems was to reproduce the potent in vitro
synergy of FCZ/BFA in animal models as we observed that a
FCZ/BFA combination failed to rescue A/J mice infected with
WT C. albicans (data not shown). One reason why the in vitro
synergy failed to translate to in vivo conditions could be that BFA
has low bioavailability characteristics [72] and efforts to chemically
improve these unfavorable properties have not been successful so
far [73,74]. The ability of BFA to induce apoptosis in cancer cells
has stimulated an interest for developing BFA as an anti-cancer
therapeutic agent [75,76,77,78,79,80]. Increasing evidence also
shows that a variety of small G protein signaling pathways of the
Ras superfamily, like RHO, RAS and ARF, have been linked to
tumorigenesis [81,82,83]. Thus, despite being evolutionarily
conserved, targeting ARF activities could be beneficial not only
for antifungal, but also for cancer therapies. Clearly, one future
challenge lies in finding fungal-specific ARF activity inhibitors that
retain favorable bioavailability in vivo, a challenge that can now be
approached cost- and time-effectively through virtual screening
with both mammalian and yeast crystal structures of different ARF
cycling proteins at hand [43,44,45,46,47,48,84,85].
The age3 mutant lost tolerance to FCZ (Figure 1). This
phenomenon of losing tolerance under membrane stress is not
unique to ARF cycling. Previous work established that when
HSP90 or calcineurin is genetically or pharmacologically inhibited
in different fungal species, cells show a similar loss of tolerance and
are not able to survive membrane stress [17,18,22,86]. Additional
phenotypes that calcineurin inhibition shares with ARF inhibition
include synergism with azoles and echinocandins as well as
reduced virulence in the bloodstream of the host [17,19,87]. These
overlapping phenotypes, together with our epistasis experiments
that showed that deleting AGE3 overrides constitutive calcineurin
signaling, provide some arguments that ARF cycling and HSP90/
calcineurin-dependent processes could be coupled. Although
overlapping functions cannot be excluded, several lines of evidence
support the current model that ARF and HSP90/calcineurin
inhibition constitute two distinct mechanisms contributing to drug
tolerance. First, a triple combination of azole/calcineurin/ARF
inhibition is more efficacious than either pairwise combination at
24 hours. Second, consistent with previous observations that long
term azole resistance evolves towards HSP90/calcineurin-inde-
pendency [20], cells treated with calcineurin inhibitors plus FCZ
recover after prolonged incubation, while BFA/FCZ treated cells
do not. Finally, if ARF cycling is in fact coupled to HSP90/
calcineurin signaling, then we might expect age3 mutants to copy
other HSP90/calcineurin phenotypes besides the demonstrated
reduced virulence and drug sensitivity. One explanation, for
instance, why calcineurin mutants are avirulent is that they do not
survive in the presence of FBS or Ca
2+ ions present in host serum
[19,88]. We found, however, that age3 mutants can survive FBS
and Ca
2+ stresses (data not shown).
More work is therefore required to elucidate how ARF G
protein signaling relates to HSP90/calcineurin and other signaling
pathways that share ARF-related phenotypes. With four ARF
proteins, six ARF GAPs and seven ARF GEFs identified in yeast
so far [89], this provides a rich resource for further investigations
into which aspects of vesicle transport and ARF G protein
signaling are responsible for two important aspects of the biology
of pathogenic fungal species.
Materials and Methods
Strains, plasmids, primers and culture conditions
All strains, primers and plasmids used in this study are described
in supplementary Table S9, S10 and S11, respectively. C. albicans
mutants were constructed either with the UAU1-transposon
insertion strategy [90] or by deleting the coding sequence of
genes (Table S9). For insertion and deletion mutant construction,
at least two mutants independently derived from two distinct
heterozygous mutants were analyzed in each case. With regards to
the AEG3 gene (ORF19.3683), we propose to use AGE3 as standard
name for the C. albicans homolog of S. cerevisiae’s GCS1, because
another gene (ORF19.5059) has already been named ‘GCS1’ in the
Candida literature [91]. For the AGE3 deletion mutant, long 100-
mer primers flanking up- and downstream sequences, respectively,
of the coding sequence of AGE3 were used to amplify marker
cassettes pFA-HIS1 and pFA-ARG4 [92]. Transformation was
carried out according to standard protocols [93] and selected on
synthetic media (2% dextrose, 6.7% yeast nitrogen base without
amino acids, 2% agar) containing the necessary auxotrophic
supplements. Correct marker integration was PCR-verified as
described [94]. As genetic manipulation in C. albicans can
frequently lead to aneuploidy [95,96], we verified the absence of
any chromosomal rearrangements by Comparative Genome
Hybridization (CGH) and found that deletion mutants of AGE3
were aneuploidy free (Figure S4). For constructing the AGE3-
revertant strain, the SAT1 flipper cassette was used [97]. Briefly,
the AGE3 coding sequence including upstream and a short
downstream flanking sequence was amplified with primers
oEE242/oEE243, KpnI/XhoI-digested and cloned into the KpnI/
XhoI-digested pSFS2A plasmid, resulting in plasmid pCaEE25,
which was sequenced. A long downstream flanking sequence of
AGE3 was amplified with primers oEE237/oEE238, NotI/SacII-
digested and then cloned into the NotI/SacII-digested plasmid
pCaEE25, resulting in plasmid pCaEE27. Following KpnI/SacII
double digestion of plasmid pCaEE27, this digestion was
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done on YPD plates containing 200 mg/ml nourseothricin, as
described [67] and PCR-verified. Counterselection of the
nourseothricin marker was done as described [67].
The nourseothricin marker cassette [97] was also used to delete
AGE3 in FCZ-resistant strains F5, S2 and DSY2146. Briefly, a
long upstream coding sequence of AGE3 was first amplified from
pEE27 with primers oEE235/oEE236, Kpn1/Xho1 digested and
then cloned into the Kpn1/Xho1 digested plasmid pEE27, therefore
replacing the coding sequence of AGE3. The resulting plasmid was
designated pEE43.
Candida strains were routinely cultured at 30uC in either rich
YPD media (1% yeast extract, 2% peptone, 2% dextrose,
supplemented with 50 mg/ml uridine) or RPMI-MOPS media
(RPMI-1640, SIGMA, supplemented with 0.3 g/l L-glutamine,
50 mg/ml uridine, 2% glucose, pH adjusted with MOPS buffer to
7.0). Media plates were supplemented with 2% agar. A. fumigatus
was cultured in half-strength YPD media (not enriched with
uridine) or RPMI-MOPS media (not enriched with uridine).
Media plates were supplemented with 1.5% agar.
Antifungal susceptibility testing
Because drug susceptibility results did not differ significantly
between WT C. albicans strains SC5314 (isolate) and SN95 (a
standard laboratory auxotrophic mutant used to construct deletion
mutants) [98] (Table S2), WT usually refers to SN95 unless
indicated otherwise. Drug stock solutions were prepared using
ethanol/10% Tween 20 as solvent for FK506 (5 mg/ml),
cyclosporin A (25 mg/ml), DMSO for fluconazole (300 mg/ml),
miconazole (100 mg/ml), ketoconazole (16.6 mg/ml), itracona-
zole (10 mg/ml), amphotericin B (20 mg/ml), calcofluor white
(50 mg/ml), brefeldin A (20 mM), hygromycin B (50 mg/ml), and
water for caspofungin (10 mg/ml). All drugs were obtained from
Sigma, except caspofungin (Merck), fluconazole and itraconazole
(both from SpectrumChemical, Mfg Corp, USA). Once in
solution, drugs were stored at 220uC. Initial antifungal sensitivity
testing with all C. albicans FCZ-cidal candidates was done using a
modified version of the CLSI (formerly NCCLS) procedure [99].
Briefly, 50 ml of drugs at two-fold the final concentration was
serially diluted in flat-bottom 96-well tissue culture plates (Corning
Inc., NY, USA) and combined with 50 ml of overnight Candida
cultures adjusted to 1610
4 cells/ml. MIC plates were incubated at
30uC without shaking and optical densities were read at indicated
time points with a Tecan Safire plate reader. The MIC was
determined by the first well with a growth reduction of .95% in
terms of OD600 values in the presence of a compound compared to
untreated control cells. Before the 72 hours OD600 readings, plates
were carefully shaken, so that a representative aliquot of 2 mlo f
each well could be spotted on fresh YPD recovery plates to assess
the extent to which cells recover from the drug treatments.
Recovery plates were incubated at 30uC between 24 hours and
48 hours before being photographed. Drug susceptibilities of
robust hits that resulted from this initial MIC testing were then
confirmed on solid media plates containing FCZ, disc diffusion or
time-kill curve assays, as described [19].
Dose-matrix titration assays were used to evaluate drug
synergies. Briefly, dose-matrix titration assays were done as
described for the MIC assays, except that the final volume was
150 ml; 50 ml of three-fold the final drug concentration of drug A
was dispensed in two-fold serial dilution steps across seven columns
of the plate, 50 ml of three-fold the final drug concentration of
drug B was dispensed in two-fold serial dilution steps down seven
rows of the plate; 50 ml of overnight Candida cultures adjusted to
1.5610
4 cells/ml was dispensed in all drug containing wells plus
one control well containing no drugs. Synergy of a compound pair
was quantified with respect to the Loewe additivity model [100]
via the fractional inhibitory concentration index (FIC index)=
(MICA in combo/MICA alone) + (MICB in combo/MICB alone), where
‘‘MICA in combo’’ is the MIC of drug A in combination,
‘‘MICA alone’’ is the MIC of drug A alone, ‘‘MICB in combo’’ is
the MIC of drug B in combination and ‘‘MICB alone’’ is the MIC of
drug B alone, respectively. Compound pairs were classified as
synergistic if its FIC index is #0.5, the standard threshold
[100,101]. For calculation purposes of the FIC index, MIC values
of .1, .2, .8, .16, .64, .128, .2048, .4096 were assumed
to be 2, 4, 16, 32, 128, 256, 4096, 8192, respectively. MIC and
dose-matrix titration results were visualized with TreeView version
1.6 (http://rana.lbl.gov/EisenSoftware.htm).
A. fumigatus disc diffusion assays were done as described [16],
with the following modifications. Conidiation was induced on
YPD plates incubated at 37uC for seven days. Conidia were then
washed off the plates and suspended in PBS+0.1% Tween media
before spreading 1610
5 conidia on appropriate plates. Discs
containing 6.4 mg caspofungin were applied and the plates were
incubated at 35uC for 48 hours. A. fumigatus MIC assays were done
exactly as described [102]. All MIC and dose-matrix titration
assays with Candida and Aspergillus were independently performed
on at least two different occasions.
Virulence studies
Virulence testing of C. albicans was done as previously described
[58]. Briefly, 8- to 12-week old C57BL/6J or A/J mice (Jackson
Laboratories, Bar Harbor, ME) were inoculated via the tail vein
with 200 ml of a suspension containing 3610
5 C. albicans in PBS.
Mice were closely monitored over a period of maximally 21 days
for clinical signs of disease such as lethargy, ruffled fur, or hunched
back. Mice showing extreme lethargy were considered moribund
and were euthanized. All experimental procedures involving
animals were approved by the Biotechnology Research Institute
Animal Care Committee, which operates under the guidelines of
the Canadian Council of Animal Care. Statistical analysis of
survival curves as well as fungal load was done with GraphPad
Prism version 5.0b. For kidney sections, extracted organs were
fixed in 10% formaldehyde (Sigma) and processed at the Histology
Core Facility at McGill (http://cancercentre.mcgill.ca/) by
staining thin slices of tissue sections with Grocot–Gomori
methenamine silver to visualize fungal cells.
Microarray and CGH studies
Comparative Genome Hybridization (CGH) analysis was done
as previously described [49] with the following modifications.
Genomic DNA was extracted from a C. albicans culture grown to
saturation with the Qiagen Genomic DNA Extraction kit
according to manufacturer’s instructions. DNA hybridization
was done with the Advalytix SlideBooster for 16 hours at 42uC
according to manufacturer’s instructions.
For the fluconazole microarray experiment, overnight cultures
of C. albicans cells were diluted to OD600 of 0.05 in fresh YPD
media, grown to early logarithmic phase (OD600 0.8) and split into
two 50 ml cultures in 250 ml Erlenmayer flasks. One culture was
fluconazole treated (600 mg/ml), while the other group received
an equal amount of DMSO as control. Cultures were grown for
one hour, spun down, the supernatant was removed and the cell
pellet was nitrogen-flash frozen and stored at 280uC until further
use. RNA was extracted according to the hot-phenol protocol
[103]. For the caspofungin microarray experiment, logarithmically
growing cells were treated with 125 ng/ml caspofungin for one
hour, as previously described [52]. RNA was extracted with the
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hybridization and slide washing was done as described [104],
except that the SlideBooster was used for hybridization. At least
three biological replicates including dye swaps were used for each
condition on double spotted ORF microarrays (6,394 intragenic
70-mer oligonucleotide probes) [104]. Scanning was done with a
ScanArray Lite microarray scanner (Perkin Elmer). QuantArray
was used to quantify fluorescence intensities and data analysis was
carried out using Genespring v.7.3 (Agilent Technologies). To
compare overlap of different gene lists as well as analyzing Gene
Ontology enrichment, p-values were calculated using the hyper-
geometric distribution as described in the GO Term Finder
Tool web site (http://www.candidagenome.org/cgi-bin/GO/
goTermFinder). Gene lists can be found in Tables S4, S5, S6,
S7 and S8.
Supporting Information
Figure S1 Phenotypes of the predicted FCZ-cidal genes in C.
albicans as determined on rich media containing FCZ. Five-fold
serial dilutions starting with an overnight culture diluted to OD600
of 0.1 was spotted (2 ml) on YPD or YPD + 2 mg/ml FCZ. Plates
were incubated at 30uC for the time indicated.
Found at: doi:10.1371/journal.ppat.1000753.s001 (5.05 MB TIF)
Figure S2 BFA synergy with different azoles in synthetically
defined RPMI media at 30uC. (A) Prior to synergy testing, C.
albicans WT strain was tested for drug sensitivity, which was
measured over time on day one (24 hours), day three (72 hours)
and day six (144 hours), respectively. Data was analyzed as in
Figure 1A. (B) Optical densities of dose-matrix titration assays
were measured on day three (72 hours) or day six (144 hours),
respectively. Additionally, spot assays were done on day six.
Except for media, assays were performed and analyzed as in
Figure 1A and 3B.
Found at: doi:10.1371/journal.ppat.1000753.s002 (2.15 MB TIF)
Figure S3 Core transcriptional responses to FCZ or CF are not
significantly affected in the absence of AGE3. (A) Transcriptional
analysis under FCZ treatment. Significantly regulated genes (.2
fold change, p-value ,0.05) were selected when WT was treated
with FCZ (WT+FCZ vs. WT) and combined with significantly
regulated genes when age3 cells were FCZ treated (age3+FCZ vs.
age3) to build a cluster tree (top). The same gene list was used to
visualize in the Venn diagram (bottom) a significant overlap of core
FCZ-responsive genes. (B) Transcriptional analysis under CF
treatment. Gene lists were selected in the same way as described
for the FCZ treatment to build a cluster tree. The Venn diagram
illustrates that there is a significant overlap of core CF responsive
genes. Tables S4, S5, S6, S7 and S8 list exact transcript changes for
all significantly regulated genes used in the FCZ and CF analysis.
Found at: doi:10.1371/journal.ppat.1000753.s003 (0.89 MB TIF)
Figure S4 No aneuploidies were detected in the AGE3 deletion
mutant by CGH analysis. Cy3 labeled genomic DNA from either
age3 mutants or strain BWP17 was hybridized to DNA
microarrays with Cy5 labeled genomic DNA from the reference
strain SC5314. Shown are plots of CGH (comparative genome
hybridization) analyses, where the y-axis shows the log2 fluores-
cence ratio of the mutant strains versus SC5314 and the x-axis
shows all chromosomes (1 to R). A single black rhombus represents
the log2 fluorescence ratio plotted as a function of its position in
the C. albicans’ assembly 21. In this representation, a 1.5-fold
increase in fluorescence ratio (i.e. 3 chromosome copies versus 2)
equals a log2 ratio of ,0.58. (A) CGH shows the known loss of one
end of chromosome 5 in strain BWP17. This strain is also
auxotroph for URA3, HIS1, ARG4. (B) The prototrophic age3
mutant does not have any chromosomal rearrangements as
determined by CGH.
Found at: doi:10.1371/journal.ppat.1000753.s004 (7.62 MB TIF)
Table S1 The 22 FCZ-cidal genes in S. cerevisiae and the C.
albicans homologs.
Found at: doi:10.1371/journal.ppat.1000753.s005 (0.04 MB XLS)
Table S2 Phenotypes of the predicted FCZ-cidal genes in C.
albicans as determined by MIC assay in YPD media.
Found at: doi:10.1371/journal.ppat.1000753.s006 (0.04 MB XLS)
Table S3 Drug synergy interaction as determined by FIC index.
Found at: doi:10.1371/journal.ppat.1000753.s007 (0.04 MB XLS)
Table S4 The genes listed here were significantly regulated (.2
fold, p-value ,0.05) in absence of AGE3.
Found at: doi:10.1371/journal.ppat.1000753.s008 (0.04 MB XLS)
Table S5 Fluconazole (FCZ) responsive genes as identified by
microarray analysis.
Found at: doi:10.1371/journal.ppat.1000753.s009 (0.07 MB XLS)
Table S6 This list contains the same genes as Table S5, but the
genes are colored here according to the Venn Diagram in Figure
S3A (bottom).
Found at: doi:10.1371/journal.ppat.1000753.s010 (0.07 MB XLS)
Table S7 Caspofungin (CF) responsive genes as identified by
microarray analysis.
Found at: doi:10.1371/journal.ppat.1000753.s011 (0.13 MB XLS)
Table S8 This list contains the same genes as Table S7, but the
genes are colored here according to the Venn Diagram in Figure
S3B (bottom).
Found at: doi:10.1371/journal.ppat.1000753.s012 (0.13 MB XLS)
Table S9 Strains used in this study.
Found at: doi:10.1371/journal.ppat.1000753.s013 (0.04 MB XLS)
Table S10 Primers used in this study.
Found at: doi:10.1371/journal.ppat.1000753.s014 (0.05 MB XLS)
Table S11 Plasmids used in this study.
Found at: doi:10.1371/journal.ppat.1000753.s015 (0.03 MB XLS)
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